Immunic, Inc. (NASDAQ:IMUX – Free Report) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings estimates for shares of Immunic in a report released on Thursday, August 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.74) per share for the quarter, up from their prior estimate of ($2.21). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Immunic’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Immunic’s Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.18) EPS, FY2027 earnings at ($2.47) EPS, FY2028 earnings at ($1.45) EPS, FY2029 earnings at ($0.53) EPS and FY2030 earnings at $0.40 EPS.
Immunic (NASDAQ:IMUX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.36.
Check Out Our Latest Research Report on Immunic
Immunic Price Performance
Shares of NASDAQ IMUX opened at $16.90 on Monday. Immunic has a 1 year low of $5.06 and a 1 year high of $17.17. The firm has a 50-day moving average of $14.63 and a 200 day moving average of $12.24. The stock has a market cap of $230.52 million, a P/E ratio of -3.86 and a beta of 1.41.
Institutional Trading of Immunic
A number of institutional investors and hedge funds have recently modified their holdings of IMUX. CTC Alternative Strategies Ltd. bought a new stake in Immunic in the 1st quarter worth approximately $27,000. ADAR1 Capital Management LLC bought a new position in shares of Immunic during the 1st quarter valued at $33,000. Qube Research & Technologies Ltd bought a new position in shares of Immunic during the 3rd quarter valued at $29,000. Focus Partners Wealth lifted its holdings in shares of Immunic by 1.5% during the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after buying an additional 39,063 shares during the period. Finally, Two Sigma Investments LP purchased a new position in shares of Immunic in the 3rd quarter worth $52,000. Institutional investors own 51.82% of the company’s stock.
About Immunic
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.
Featured Articles
- Five stocks we like better than Immunic
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
